GLP-1 receptor agonist Semaglutide Research Topics:
-
Glycemic Control:
Semaglutide significantly lowers blood glucose levels in individuals with type 2 diabetes by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying (PMID: 32910488, PMID: 32910487). -
Weight Loss:
It promotes substantial weight loss by reducing appetite and increasing feelings of fullness, which helps in the management of obesity (PMID: 32910488, PMID: 32910487). -
Cardiovascular Benefits:
Semaglutide reduces the risk of major adverse cardiovascular events, including heart attack and stroke, making it beneficial for patients with type 2 diabetes at high cardiovascular risk (PMID: 32910488, PMID: 33068776). -
Anti-Inflammatory Effects:
It decreases postprandial inflammation markers such as IL-6, which contributes to better overall metabolic health (PMID: 32910488).
Related Research
The differences in weight loss percentages for GLP-1 (Semaglutide), GLP-1/GIP (Tirzepatide), and GLP-1/GIP/GCGR (Retatrutide) are as follows:
-
Semaglutide (GLP-1):
In clinical trials, Semaglutide resulted in a weight loss of approximately 12% over a period of 68 weeks (PMID: 32910488). -
Tirzepatide (GLP-1/GIP):
Tirzepatide demonstrated a weight loss ranging from 15% to 21% in different studies over a period of 72 weeks (PMID: 32910487). -
Retatrutide (GLP-1/GIP/GCGR):
In a phase 2 trial, Retatrutide showed a placebo-subtracted weight loss ranging from 6.6% to 22.1% over 48 weeks (PMID: 37366315).
Peer-Reviewed Studies
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). New England Journal of Medicine.
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … & Vilsbøll, T. (2016). N Engl J Med, 375, 1834-1844.
Structure
Sequence: HXEGTFTSDVSSYLEGQAAK
OH.steric diacid-EFIAWLVRGRG
Molecular Formula: C187H291N45O59 Molecular Weight: 4113.64 g/mol
PubChem CID: 56843331
CAS Number: 910463-68-2
Synonyms: Semaglutide, Oxempic, Rybelsus, NN9535